



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

October 24, 2023

Cameron Turtle, DPhil
Chief Operating Officer
Aeglea BioTherapeutics, Inc.
221 Crescent Street
Building 23, Suite 105
Waltham, MA 02453

Re: Aeglea BioTherapeutics, Inc.
Preliminary Proxy Statement on Schedule 14A
Filed August 8, 2023
File No. 001-37722

Dear Cameron Turtle:

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,

Division of Corporation Finance
Office of Life Sciences

cc: Branden C. Berns